SGLT2 Inhibitors in African American Patients

Current Status
Not Enrolled
Get Started

Course Description

Diabetes management strategies should treat-to-target and involve the patient in the process of his/her disease management. However, race, ethnicity, and social determinants of health influence diabetes care and management, introducing an implicit bias that can impact outcomes for patients with T2D. Emerging evidence supports the efficacy of an SGLT2 inhibitor as part of an overall management program in African-Americans with type 2 diabetes, an understudied population. By identifying individuals who will benefit from SGLT2 inhibitors, primary care physicians can work with patients to manage their T2D, thereby reducing complications and enhancing quality of life.

This enduring CME activity illustrates several case studies for appropriately prescribing SGLT2 inhibitors in African-American patients with T2D, using the overall approach algorithm developed by the ADA in its Standards of Medical Care in Diabetes--2020.2 Upon completion, viewers will learn how SGLT2 inhibitors and combination therapy may be incorporated into a treatment plan for minority patients with T2D.


  • You must login and “enroll” in this activity to participate and claim credit.
  • Your CME certificate will use the name and credentials in your profile.
    • Once you are logged in, ensure that your profile is up-to-date and correct. By clicking the "Edit Your Profile" button or by clicking here.
    • Please add your credentials to the last name field ex: "Smith, MD"
    • Click “Update” at the bottom of the page to save changes.
  • When you “complete” the activity, which should take about 20 minutes, the 3-question post-test will open automatically. Carefully read the infographic. A score of 100% is required to earn the CME certificate.
  • To begin, click the "Begin Course" button below or "Course Materials" in the navigation bar to the right or at the bottom of this page.


Click image to read bio

Eric Gertner, MD, MPH, FACP

Associate Medical Director for Quality
Lehigh Valley Physicians Group
Allentown, Pennsylvania

Read bio


Click image to read bio

Charles A. Goldthwaite, Jr.

Science Writer
Nashville, TN

Read bio



Click image to read bio

Lee Radosh, MD, FAAFP

Medical Director
Center of Excellence for Opioid Use Disorder
Reading Hospital
Tower Health System

Read bio

Course Content

Click "Course Materials" to access lessons.


This Enduring Material activity, CME Infographic: New Medications for Patients with T2DM, has been reviewed and is acceptable for up to 0.50 Prescribed credit(s) by the American Academy of Family Physicians. AAFP certification begins 01/15/2021. Term of approval is for one year from this date. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Faculty Disclosures

The following individuals have no financial conflicts of interest relevant to this activity:

William Warning, MD
Angie Halaja-Henriques
Sue Hockenberry, PCMH CCE

Eric Gertner, MD, MPH
Lee Radosh, MD, FAAFP
Charles A. Goldthwaite, Jr.

Learning Objectives

  • List the potential clinical benefits for achieving glycemic control with new medications in patients with T2DM
  • Identify how new medications and combination therapy might be used in a treatment plan